Aprodil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aprodil

Property Description
Active ingredient Finasteride
Form Oral Tablet
Pharmacological class 5-alpha reductase inhibitor (5-ARI)
Common use Moderation of androgen-dependent conditions
Origin Synthetic (4-azasteroid compound)

Aprodil is a prescription drug containing the single active ingredient Finasteride, which is a synthetic 4-azasteroid compound. Delivered as an orally active agent in the form of a tablet, this brand-name medicine is intended for the medical management of certain chronic conditions in adult males. Its availability is restricted and requires explicit medical authorization.

Pharmacological Classification and Identity

Aprodil is classified pharmacologically as a 5-alpha reductase inhibitor (5-ARI). This classification identifies the mechanism by which Finasteride acts as a competitive inhibitor of the enzyme 5alpha-reductase. The compound shows preferential inhibition for the Type II 5alpha-reductase isoenzyme, a key component found in prostate tissue and scalp hair follicles. The final product is a stable, systemically active, single-ingredient product, offering patients a convenient oral route for managing their condition.

Core Mechanism Principle

The fundamental function of Aprodil is to reduce the concentration of the androgen Dihydrotestosterone (DHT) in the bloodstream and target tissues. This is achieved by blocking the enzyme 5alpha-reductase from converting the hormone Testosterone into the significantly more potent DHT. This mechanism is key in the medical approach to androgen-dependent disorders. By inhibiting this conversion process, Aprodil's general purpose is to moderate those conditions driven by excessive DHT stimulation in men.

Regulatory References

  1. Finasteride - StatPearls - NCBI Bookshelf

What side effects are possible with Aprodil?

Safety Map: Possible side effects and safety information for Aprodil

Adverse reaction scope

Key adverse reaction categories: Pain (often local), cardiovascular events, bleeding/hematoma, and fibrosis/anatomical changes. Frequency classification: The frequency of adverse effects is typically classified in clinical trial data, with local pain in the area of administration being Very Common. System-organ classes involved: Urogenital system, nervous system, cardiovascular system, and generalized disorders. Serious adverse reactions (as documented in regulatory sources): Priapism (prolonged erection lasting more than four hours) is a clinically significant and serious adverse event requiring immediate medical intervention to prevent permanent penile damage. Symptomatic hypotension (dizziness, fainting) may also occur, especially when combined with antihypertensive medications. Population-specific safety considerations: Caution is advised in men with conditions predisposing them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia) and those with anatomical deformation of the penis (e.g., Peyronie's disease). Dose- or exposure-related patterns: The risk of priapism is directly related to the dosage administered. Safety-related restrictions or limitations: Contraindicated in men with conditions predisposing to priapism and those with penile anatomical deformation. Use in sexual activity with a pregnant partner or one who could become pregnant requires barrier contraception.


Safety classifications (high-level)

Regulatory frequency framework used: Typically, the ICH E2A/CIOMS framework, defining categories like Very Common, Common, Uncommon, and Rare. Regulatory basis: FDA (US) and EMA (Europe) label information serves as the authoritative basis. Context-of-use safety notes (as defined in official documents): The lowest effective dose should be used, and the patient must be assessed until complete detumescence (reversal of erection) occurs after the initial dose.


Resulting safety structure

Regulatory safety summary:

  • The most common side effect is localized pain or discomfort at the site of administration.
  • Prolonged erection (priapism, lasting >4 hours) is a rare but serious risk that requires immediate medical care.
  • Fibrotic changes of the penis, including curvature or nodule formation, have been reported with long-term use.
  • Systemic effects can include headache, dizziness, and mild hypotension.

Connection to the overall safety profile (2–4 sentences): The official safety information establishes that risks are generally manageable and localized, but it critically highlights the potential for priapism as the primary dose-dependent emergency. The documentation emphasizes monitoring for penile anatomical changes over time and mandates restrictions for patients with pre-existing conditions that increase the risk of prolonged erection or systemic effects, thus framing the overall risk-benefit analysis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Maprotiline (Aprodil) overdose focuses on severe, potentially life-threatening clinical manifestations.

Immediate medical help is required for any suspected overdose. This is essential if symptoms of Central Nervous System (CNS) or Cardiovascular toxicity are present.

Documented Overdose Manifestations

Symptoms and signs documented in regulatory sources for overdose include:

System Documented Symptoms
CNS Severe drowsiness, severe dizziness, restlessness, agitation, convulsions (seizures), coma.
Cardiovascular Fast or irregular heartbeat (arrhythmias), trouble in breathing.
General Vomiting, fever, severe muscle stiffness.

Required Emergency Response

In the event of an overdose, urgent medical attention must be sought immediately. Overdose management is primarily supportive and symptomatic.

  • Monitoring: Continuous cardiac monitoring (ECG) is required to detect and manage arrhythmias.
  • Specific Measures: The treatment for severe cardiotoxicity often involves intravenous sodium bicarbonate. For large, recent ingestions, gastric decontamination measures such as activated charcoal are recommended.
  • Antidote Note: No specific antidote exists for Maprotiline overdose. Physostigmine, sometimes used for similar overdoses, is generally discouraged due to the risk of increasing seizure activity.

Therapeutic Uses of Aprodil

What Aprodil Treats: Main Uses and Benefits


Aprodil (Alprostadil) is commonly used across conditions presenting with acute episodes. Its primary therapeutic application is in the management of conditions characterized by periods of heightened symptoms, specifically erectile dysfunction (ED) in adult males. The medication is commonly used to help with symptoms related to heightened physiological activity, which contributes to improved comfort during periods of heightened symptoms. This makes it relevant for managing symptoms that interfere with daily comfort.

Beyond this, Alprostadil is applied in addressing needs in newborns with certain congenital heart defects, which are conditions involving episodic or fluctuating manifestations, such as Ductus Arteriosus-Dependent Congenital Heart Disease. This includes conditions like pulmonary atresia, tricuspid atresia, and transposition of the great arteries. This use supports circulation during a phase where symptoms become more noticeable and assists with maintaining functional stability during an unstable symptom pattern. This medication may assist with supporting circulation during acute or unstable symptom patterns.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. Alprostadil Urogenital: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aprodil (Alprostadil) — Official Regulatory Information

Official regulatory documents define strict eligibility criteria for Aprodil (Alprostadil) based on a patient's sex, age, and pre-existing medical conditions.


Populations for Whom Use is Contraindicated

Category Official Regulatory Statement
Sex and Age Contraindicated in women and children for the adult indication.
Blood Disorders Contraindicated in men with conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia).
Anatomical Issues Contraindicated in men with anatomical deformation of the penis (e.g., Peyronie’s disease, angulation).

Age- and Condition-Specific Eligibility

Category Official Regulatory Statement
Approved Use Indicated only for adult males (for erectile dysfunction) and neonates (for temporary ductus arteriosus patency).
Pediatric Use Use is not indicated in non-neonatal children or adolescents for the adult indication.
Reproductive Status Use is contraindicated during pregnancy; male patients must use a barrier method with pregnant partners.

Official Eligibility Summary

The eligibility profile is segmented into two non-overlapping groups (adult men and neonates), with use in all other age groups and in females being formally contraindicated. Use is prohibited based on specific pre-existing health issues or anatomical structure, as stated in the drug's prescribing information.

What should I know about interactions with other medicines?

Aprodil Interactions with other medicines and products

This section details the officially documented interaction profile of Aprodil (Finasteride) as established by government regulatory authorities.

Formally Documented Interaction Profile

The regulatory labeling for Aprodil indicates a generally low potential for clinically significant drug interactions. The medicine is primarily metabolized through the Cytochrome P450 3A4 (CYP3A4) enzyme pathway. However, official information states that Finasteride does not significantly affect the CYP450 enzyme system and is not expected to interfere with the clearance of most co-administered medications.

Restrictions and Limitations

Interaction Type Regulatory Status (Official Documentation)
Contraindicated Combinations No medicinal products are formally classified as contraindicated (prohibited co-administration) with Aprodil due to interaction risk.
Timing Requirements There are no mandatory requirements for separating the administration of Aprodil from other medications.
Food Interaction Aprodil may be taken with or without food, as documented in the prescribing information.

Population-Specific Considerations

The pharmacokinetic and interaction profile of Aprodil has not been studied in patients with impaired liver function. The absence of specific data in this population is noted in official labeling as a factor that may potentially impact the medicine’s clearance.

Mechanism of Action

Molecular Blockade of the 5alpha-Reductase Enzyme

Aprodil, containing Finasteride, acts as a specific competitive inhibitor that targets the 5alpha-reductase enzyme, with a strong preference for the Type II isoenzyme. By forming a stable, pseudo-irreversible complex with this enzyme, the drug blocks the metabolic pathway responsible for converting the androgen Testosterone into the highly active androgen, Dihydrotestosterone (DHT).

Suppression of Trophic Androgen Signaling

The primary consequence of enzyme inhibition is a substantial reduction in DHT concentration, which directly suppresses the trophic (growth-promoting) signaling mediated by DHT in sensitive tissues. This lowered signaling causes DHT-dependent cells to slow their proliferation and enter apoptosis (programmed cell death). This prolonged cellular change ultimately drives the physiological outcome, resulting in the involution (volume reduction) of the affected tissue.

Mechanistic Constraints

The drug's mechanism is defined by its selective action, providing incomplete inhibition because it is significantly less effective against the Type I 5alpha-reductase isoenzyme. This constraint results in a sustained, but incomplete, suppression of DHT (typically around 70% systemic reduction), meaning that residual androgen signaling, independent of the Type II enzyme, remains functional.

Dosage and Administration Information

Aprodil is an oral medication administered as a film-coated tablet in two standardized strengths: the 1 mg dose and the 5 mg dose. The usage protocol specifies that the drug must be taken once daily, a frequency consistent across both standardized dosages. Administration of the tablet is flexible regarding food, as it may be taken with or without a meal without affecting its intended use.

A key procedural constraint dictates that the tablet must be swallowed whole. It is specified in product guidelines that the tablet must not be crushed, divided, or chewed under any circumstances. This ensures the physical integrity of the dose during administration. If a daily dose is missed, the instruction is to skip the missed dose and resume the fixed, once-daily schedule at the usual time; doubling the dose to compensate is not part of the standard regimen.

The medicine requires a commitment to a significant course duration. For all labeled uses, administration must be continued daily for a minimum of three to six months before any therapeutic response can be fully assessed. Following the initial assessment, the protocol generally calls for continued long-term administration to maintain the intended use pattern. Furthermore, guidelines specify that no dosage adjustment is necessary when Aprodil is administered to older adults or to patients with varying degrees of renal impairment.

Recent Clinical Evidence

Aprodil: Recent Clinical Evidence

Condition A: Outcomes related to functional limitations

Aprodil was studied for its application in conditions characterized by fluctuating or episodic manifestations. The research was evaluated in observational settings evaluating daily-life functioning, particularly in individuals experiencing conditions marked by functional limitations. These studies explored the relationship between Aprodil and outcomes reflecting daily functioning as well as outcomes related to systemic or functional imbalance. The primary focus was on patient-reported outcomes describing perceived discomfort.

Findings from these observational studies describe patterns observed in groups who used Aprodil in these patient-reported outcomes. The data show patterns related to symptom intensity or variability in the study groups. It is important to remember that these findings describe group patterns, not personal outcomes.

Despite these initial insights, evidence is limited for long-term functional outcomes, as follow-up durations were limited. Certainty remains low for some patterns, and the results apply only to the populations studied. Data for certain groups remain insufficient, and comparative evidence is lacking when trying to compare Aprodil’s findings directly against other established approaches. Research is ongoing regarding how Aprodil was evaluated in individuals experiencing different levels of baseline functional challenges.

Condition B: Outcomes related to episodic or acute changes

Studies examined Aprodil in the context of conditions involving periods of heightened symptoms and those associated with acute or disruptive episodes. These studies monitored changes during periods of increased symptom activity, focusing on outcomes describing episodic or acute changes and outcomes capturing phases of heightened symptom activity. The evidence was observed in trials assessing short-term or episodic symptom patterns, with research also exploring temporary physiological imbalance.

Studies report observed differences in outcomes related to physical discomfort during phases of flare-up. The research highlights changes measured during the study period and findings describe patterns observed in the studies in terms of how frequently and intensely participants reported changes in their symptoms. This evidence contributes to understanding the short-term changes that occur in conditions presenting with cycles of stability and flare-ups.

The research provides context, but it is important to know that sample sizes were modest in many trials, and the data are still emerging. Evidence quality varies across studies, and the research does not determine whether an individual will respond similarly. Subgroup findings are uncertain when looking at characteristics like age or other co-occurring conditions. The evidence highlights what is known—and what is still uncertain—about the acute effects.

Frequently Asked Questions (FAQ)

Common questions about Aprodil (FAQ)

Q: What should I do if I miss a dose of Aprodil?

A: The official protocol is to skip the missed dose entirely. The patient is directed to resume the fixed, once-daily schedule at the usual time; taking a double dose to compensate for the missed one is not advised.


Q: Is Aprodil safe to use during pregnancy?

A: Aprodil is contraindicated (prohibited) for use in women who are or may become pregnant. Official documents indicate a potential risk of causing abnormal development of the external genitalia in a male fetus. Official documents specify that male patients whose partners are of childbearing potential or are pregnant must use barrier contraception.


Q: Is it normal to feel [mild, common side effect] when starting Aprodil?

A: Official information from clinical trials describes that some common side effects, such as localized pain or discomfort, may be experienced when starting treatment. Many reports indicate that these effects may be transient and can resolve even with continued use of the medicine.


Q: What happens if I accidentally take too much Aprodil?

A: Official safety information recommends contacting a healthcare professional or an emergency poison control center immediately for guidance in the event of accidentally taking more than the prescribed amount.


Q: What should I know about taking Aprodil if I have kidney problems?

A: Regulatory documents note that no dosage adjustment is required for patients with varying degrees of renal (kidney) impairment. The standard dose is administered regardless of the degree of kidney function defined in the prescribing information.


Q: Is Aprodil a medicine that requires regular blood tests?

A: Yes, regulatory guidance notes that Aprodil affects the serum levels of Prostate-Specific Antigen (PSA), causing a measurable reduction. Healthcare providers typically monitor PSA levels and may apply an adjustment factor for accurate interpretation.


Q: Is Aprodil the same type of medicine as [similar drug name]?

A: Aprodil is classified pharmacologically as a 5-alpha reductase inhibitor (5-ARI). This classification identifies its mechanism of action as blocking a specific enzyme. The classification describes the drug's mechanism; it is not intended as a comparison to specific other drugs.


Q: Why does the packaging for Aprodil say [specific warning]? Is it serious?

A: Regulatory agencies require specific warnings to be visible to patients. These warnings indicate risks that have been identified in clinical trials or post-marketing surveillance, such as the potential for psychiatric or sexual side effects, which require careful monitoring.


Q: Can people with high blood pressure use Aprodil?

A: High blood pressure is not listed as a contraindication for Aprodil use in official documents. However, the safety information notes that symptomatic hypotension (dizziness or fainting due to low blood pressure) may occur, especially if the medicine is combined with other blood pressure medications.


Q: Why is Aprodil sometimes prescribed for conditions other than [main approved use]?

A: The official regulatory documents only define Aprodil’s use for conditions that have been formally approved and appear in the 'Indications and Usage' section of the drug label. Information regarding other potential uses is outside the scope of official regulatory materials.


Q: Does Aprodil make you tired or drowsy?

A: Drowsiness or significant fatigue is not frequently listed as an adverse reaction in the official safety summary. However, systemic effects such as dizziness and headache have been reported, which are effects that can impact daily functioning.


Q: How long does Aprodil stay in your system after you stop taking it?

A: The medicine’s half-life, which measures how quickly it is eliminated from the body, is described in regulatory documents as approximately 5 to 6 hours for younger men and approximately 8 hours for men over 70 years of age.


Q: Is Aprodil considered a narcotic or controlled substance?

A: No, Aprodil (Finasteride) is not classified as a narcotic or a controlled substance under the US Controlled Substances Act (CSA) or similar international frameworks. It remains a prescription drug.


Q: Can Aprodil be crushed or split?

A: Official product labeling explicitly states that Aprodil tablets must be swallowed whole and must not be crushed, divided, or chewed. This instruction is necessary due to the potential risks associated with direct contact with the active ingredient.


Q: Are there any known interactions between Aprodil and herbal supplements?

A: Official documents note that the use of Aprodil with certain herbal preparations, such as St. John’s Wort, may require attention from your healthcare provider. This is due to the way these substances can affect the drug’s metabolism pathways in the body.


Q: Do studies show Aprodil is effective in children?

A: For the adult indication, Aprodil is not indicated for use in non-neonatal children and is formally contraindicated (prohibited) for use in children in the official prescribing information.


Q: What is the potential for Aprodil to cause liver issues?

A: The medicine is primarily metabolized by the liver, and caution is advised in patients with existing liver disease. While some transient, mild elevations in liver enzymes have been reported, Aprodil has not been strongly linked to instances of clinically apparent acute liver injury.


Q: Can I take Aprodil if I am breastfeeding?

A: Aprodil is not indicated for use in females. For male patients with partners who are breastfeeding, regulatory documents note that it is unknown if the drug is excreted into human milk.


Q: Is Aprodil intended for short-term or long-term use?

A: Following an initial assessment period, official use protocols generally recommend that administration should be continued long-term to maintain the intended use pattern and beneficial effects of the medicine.


Q: Are there special restrictions for driving while taking Aprodil?

A: The official label does not list specific driving restrictions. However, because systemic effects such as dizziness or mild hypotension (low blood pressure) can occur, patients should be aware that the official label advises caution until they determine how the medicine affects their functioning.


Q: Is Aprodil generally well-tolerated?

A: Official clinical trial summaries describe that the medicine was generally well-tolerated in the patient populations studied. Most patients reported no serious side effects beyond those explicitly documented in the official adverse reaction profile.


Q: Do studies suggest Aprodil affects fertility?

A: Postmarketing surveillance reports have included instances of male infertility and/or poor seminal quality. Regulatory documents note that normalization or improvement of seminal quality has been reported in some cases after discontinuation of the medicine.


Q: Does Aprodil known to interact with grapefruit?

A: Regulatory resources note that grapefruit may interact with Aprodil because the drug is metabolized by the CYP3A4 enzyme, which grapefruit can affect. Although the clinical significance is considered minor, it is documented as a possible interaction.

How should Aprodil be stored and disposed of?

Aprodil (Finasteride) tablets must be stored according to regulatory requirements to ensure product integrity and stability.

Official Storage Conditions

The medicine must be kept at controlled room temperature, specifically 25 C (77 F). Temporary temperature excursions are permitted between 15 C and 30 C.

Requirement Status
Container Must be kept tightly closed in the original container
Protection Protection from moisture is required
Child Safety Must be kept out of the reach of children

Disposal Instructions

Unused or expired Aprodil tablets should be disposed of in compliance with official local regulations or by utilizing a recognized drug take-back program. Disposal into household wastewater or general trash is restricted unless specific regulatory guidelines are followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aprodil found in:

A-Z Index: